Sean McCarthy, CytomX CEO
Regeneron throws struggling CytomX a lifeline with $30M cancer bispecific deal
Regeneron is teaming up with a biotech that has struggled after axing its lead program just four months ago.
The big biopharma signed a licensing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
